LabGenomics Faces Continued Delisting Concerns; Must Keep Share Price at ₩1,000 for 21 Consecutive Days
Predicted impact: Medium
Delisting risk already covered in recent filings; share price must hold ₩1,000 for 21 days, lowered one level.
LabGenomics랩지노믹스
084650 · KOSDAQ · ₩084650 · 랩지노믹스
₩2,095▲ ₩85 (4.23%)End-of-day · Oct 30, 2026 · End-of-day prices.
Price · 1Y −81.21%
- Market cap
- ₩31B
- Enterprise value
- ₩64B
- P/E
- —
- P/B
- 0.2×
- Dividend yield
- 0.0%
- ROE
- −34.9%
- Net margin
- −66.5%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−82.4% from the high
₩1,500Today: ₩1,913 – ₩2,095₩11,925
Returns
- 1W+23.2%
- 1M−19.9%
- 3M−23.4%
- 6M−68.4%
- YTD−76.9%
- 1Y−81.2%
- Volume today
- 46,256
- 0.3× the 20-day average
- Traded today
- ₩94M
- Listed shares
- 14,847,998
- EPS (12 months)
- −₩3,475
- Earnings yield −165.9%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 31 of 100 (50 is a normal day for this stock).
- SentimentNegativeNews: Delisting filings are a negative signal for shareholders, though the filings themselves give little detail. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-17% over the last month; the price is below its 20-day average.
- News impactHigh4 news items and filings in two weeks; 1 rated high impact, 2 medium.
Signals describe activity, not recommendations. Not financial advice.
LabGenomics stock overview
LabGenomics (랩지노믹스, KRX: 084650) is listed on KOSDAQ, in the Biotech & Pharma sector. LabGenomics is a South Korean molecular diagnostics company offering prenatal genetic screening such as non-invasive prenatal testing, cancer gene tests, and chromosomal abnormality tests, using PCR, immunodiagnostic and next-generation sequencing technologies. Its shares closed at ₩2,095 on Oct 30, 2026, up 4.23% on the day, giving it a market value of ₩31B.
Key facts
- Market cap
- ₩31B
- Sector
- Biotech & Pharma
- Latest price change
- +4.23%
- As of
- Oct 30, 2026
- Main business
- LabGenomics is a South Korean molecular diagnostics company offering prenatal genetic screening such as non-invasive prenatal testing, cancer gene tests, and chromosomal abnormality tests, using PCR, immunodiagnostic and next-generation sequencing technologies.
Quick answers about LabGenomics
- What does LabGenomics do?
- LabGenomics is a South Korean molecular diagnostics company offering prenatal genetic screening such as non-invasive prenatal testing, cancer gene tests, and chromosomal abnormality tests, using PCR, immunodiagnostic and next-generation sequencing technologies. Its MomGuard prenatal test line is used by patients through a broad network of over 3,000 medical institutions in Korea, and it also sells diagnostic kits. The company has expanded in the United States through its acquisitions of two CLIA laboratories, QDx Pathology Services and Integrated Molecular Diagnostics, which serve hospitals and clinics across the country.
- What is the market cap of LabGenomics?
- The market capitalisation of LabGenomics was ₩31B at the close on Oct 30, 2026.
- Who are the largest shareholders of LabGenomics?
- According to the latest official filings, the largest reported holders are Luha Private Equity (27.96%, as of Sep 30, 2026); Ruhagalraktikos (27.54%, as of Sep 30, 2026); Stick Litmus (18.38%, as of May 28, 2026).
- When is the next earnings report from LabGenomics?
- Korean companies rarely announce results dates in advance. Based on when LabGenomics filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own LabGenomics?
- Yes. The National Pension Service held 0.58% of LabGenomics shares as of Dec 31, 2023.
Company profile
LabGenomics is a South Korean molecular diagnostics company offering prenatal genetic screening such as non-invasive prenatal testing, cancer gene tests, and chromosomal abnormality tests, using PCR, immunodiagnostic and next-generation sequencing technologies. Its MomGuard prenatal test line is used by patients through a broad network of over 3,000 medical institutions in Korea, and it also sells diagnostic kits. The company has expanded in the United States through its acquisitions of two CLIA laboratories, QDx Pathology Services and Integrated Molecular Diagnostics, which serve hospitals and clinics across the country.
Written by AI from the company's latest annual report.
- Korean name
- 랩지노믹스
- Sector
- Biotech & Pharma
- CEO
- 류재학 대표이사
- Founded
- Mar 2002
- Listed
- Dec 2014
- Listed shares
- 14,847,998
- Fiscal year ends
- Month 12
- Website
- www.labgenomics.co.kr
Similar companies
- Samsung Biologics207940 · ₩69T₩1,487,000+8.86%
- Celltrion068270 · ₩44T₩191,600+1.22%
- Alteogen196170 · ₩15T₩211,500−3.86%
- SK biopharmaceuticals326030 · ₩6.1T₩77,700−0.13%
- Yuhan000100 · ₩5.5T₩75,100+0.54%
- HLB028300 · ₩5.3T₩40,000+0.76%
- Hanmi Pharm128940 · ₩5.3T₩415,000+6.82%
- SAM Chun Dang Pharm000250 · ₩4.3T₩182,700−3.13%
Recent news
Recent filings
See all- Amended: DelistingOct 30, 2026
- DelistingOct 30, 2026
- Share buyback decisionOct 23, 2026
- Insider shareholding reportSep 30, 2026
- Insider shareholding reportSep 30, 2026
Titles in Korean until English translations are added.
Also known as: LabGenomics / 랩지노믹스 / 084650 / KRX:084650
Source: KRX statistical information